Lindis Biotech Appeals $50M Verdict Reversal in Patent Dispute With Amgen
Lindis Biotech has challenged a Delaware federal judge’s decision that overturned a $50 million infringement verdict in their favor against Amgen. The biotech company argues that the judge erroneously concluded that an inventor engaged in deceitful conduct towards the United States Patent and Trademark Office (USPTO) during the patent prosecution process. Lindis, a German company,…